$VVOS

Vivos Therapeutics (VVOS) partners with South Palm Cardiovascular Associates to establish a Sleep & Airway Medicine Center in Florida. Vivos will hold 75% of the new entity, AIM Florida, with plans to start operations in Q1 2027. The center aims to treat 250 patients monthly, generating up to $6M annual revenue with 30%+ margins. SPCVA will expand referrals for sleep disorder-related conditions. VVOS stock is currently at $0.25, up 0.58%.

Vivos Therapeutics (NASDAQ:VVOS) said the U.S. Patent and Trademark Office issued U.S. Patent No. 12,697,190, a continuation of a 2024 patent, to broaden IP protection for its Vivos CARE oral device technology for obstructive sleep apnea. The company says the layered patents are harder for competitors to design around and support its FDA-cleared devices for severe adult and pediatric OSA.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth under Item 5.02 of this Current Report on Form 8-K regarding the Separation, Resignation and Executive Transition Agreement, dated as of July 31, 2026 (the “ Separation Agreement ”), between Vivos Th

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June [_], 2026, between Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signatur

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001716166 0001716166 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 COLLABORATION AGREEMENT This Collaboration Agreement (this “ Agreement ”) is entered into as of June 9, 2026 (the “ Effective Date ”), by and between Vivos Therapeutics, Inc. , a Delaware corporation with principal offices at 7921 Southpa

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ex10-1.htm EX-10.1 Exhibit 10.1 THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED. Exchange Agreement This Exchange Agreement (this “ Agreement ”) is executed as of June 5, 2026 by

Vivos Therapeutics, Inc. reported its first-quarter 2026 financial results, with revenue increasing by 70% year-over-year to $5.14 million. Despite the revenue growth, the company's net loss attributable to stockholders widened to $(7.68) million, and diluted loss per share increased to $(0.52). The revenue growth was primarily driven by sleep testing services and treatments from the recently acquired SCN network, with the company shifting its sales model towards medical providers and expanding its service offerings.